Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.436 USD | -4.09% | -10.16% | +41.10% |
May. 15 | Brookline Capital Upgrades Dare Bioscience to Buy From Hold, Price Target is $3 | MT |
May. 14 | Transcript : Daré Bioscience, Inc., Q1 2024 Earnings Call, May 14, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+41.10% | 43.85M | |
+67.53% | 63.85B | |
-0.77% | 41.83B | |
+45.66% | 40.65B | |
-10.72% | 27.12B | |
+13.30% | 26.52B | |
-22.79% | 18.69B | |
+4.70% | 12.73B | |
+24.10% | 12.11B | |
+27.41% | 12.07B |
- Stock Market
- Equities
- DARE Stock
- News Daré Bioscience, Inc.
- Dare Bioscience : Roth Capital Adjusts Price Target on Dare Bioscience to $11 From $9, Maintains Buy Rating